Cooperative Estrogen Replacement Therapy (CERT)
Cooperative Estrogen Replacement Therapy (CERT) is a NaProTechnology protocol, developed by Dr. Thomas W. Hilgers, that targets estrogen deficiency across the reproductive cycle in specific clinical indications, including deficient cervical mucus production, selected subtypes of luteal phase deficiency, and other restorative care contexts where estrogen output is inadequate.1
CERT is conceptually distinct from postmenopausal hormone replacement therapy. It addresses estrogen deficiency in reproductive-age women within an active cycle context, guided by Peak Day charting and hormonal assay results. The mucus cycle is a direct biomarker of estrogen activity in the pre-Peak phase, and deficient or absent mucus is one clinical presentation that may indicate a need for estrogen evaluation. Inadequate estrogen in the pre-Peak phase can impair both cervical mucus quality and the uterine environment.2
As with CPRT, the word "cooperative" reflects the design intention: estrogen support is timed and calibrated to cooperate with the body's cycle, not to impose a fixed daily replacement dose regardless of cycle phase. The treating clinician determines the specific drug, dose, route, and timing based on each patient's chart data and assay findings. CERT uses isomolecular hormones, preparations chemically identical to endogenous estradiol, consistent with NaProTechnology's preference for physiologic-pattern matching over pharmacologic substitution.3
CERT operates within the broader NaProTechnology medical management framework. Estrogen is a co-regulator of the entire reproductive cycle, and its adequacy in both pre-Peak and post-Peak phases affects follicle development, uterine receptivity, and luteal function. CERT reflects the NaProTechnology principle that restoring hormonal output, rather than bypassing it, is the clinical goal. Options include transdermal estrogen preparations among other routes, with selection individualized to the patient's clinical picture.
Cited in this entry
- Hilgers TW. The Medical and Surgical Practice of NaProTECHNOLOGY. Pope Paul VI Institute Press; 2004. https://rrmacademy.org/library/the-medical-surgical-practice-of-naprotechnology-rectiyuppdjrktphh/
- Hilgers TW. The NaProTECHNOLOGY Revolution: Unleashing the Power in a Woman's Cycle. Beaufort Books; 2010. https://rrmacademy.org/library/the-napro-technology-revolution-unleashing-the-power-in-a-womans-cycle-rec9momrwqgzcmhnb/
- Hilgers TW, Keefe CE, Pakiz KA. The Use of Isomolecular Progesterone in the Support of Pregnancy and Fetal Safety. Issues Law Med. 2015. https://rrmacademy.org/library/the-use-of-isomolecular-progesterone-in-the-support-of-pregnancy-and-fetal-safet-rec9gz3n4iplw6vym/
This content is for educational purposes only and does not constitute medical advice. Consult an RRM clinician or healthcare provider for guidance specific to your situation.